Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD036
MIFTS: 48

Bile Duct Disease malady

Categories: Gastrointestinal diseases, Liver diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bile Duct Disease

About this section

Aliases & Descriptions for Bile Duct Disease:

Name: Bile Duct Disease 12 14
Bile Duct Diseases 41 42 69
Bile Duct Disorder Nos 12
Disorder of Bile Duct 12

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases Liver diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4138
MeSH 42 D001649
NCIt 47 C96716
SNOMED-CT 64 118926004 197455006
UMLS 69 C0005395
Sources

Summaries for Bile Duct Disease

About this section
MedlinePlus : 41 your liver makes a digestive juice called bile. your gallbladder stores it between meals. when you eat, your gallbladder pushes the bile into tubes called bile ducts. they carry the bile to your small intestine. the bile helps break down fat. it also helps the liver get rid of toxins and wastes. different diseases can block the bile ducts and cause a problem with the flow of bile: gallstones, which can increase pressure in the gallbladder and cause a gallbladder attack. the pain usually lasts from one to several hours. cancer infections birth defects, such as biliary atresia. it is the most common reason for liver transplants in children in the united states. inflammation, which can cause scarring. over time, this can lead to liver failure. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Bile Duct Disease, also known as bile duct diseases, is related to common bile duct disease and cholangitis, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Bile Duct Disease is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Metabolism and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Clonidine and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and small intestine, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Wikipedia : 71 A bile duct is any of a number of long tube-like structures that carry... more...

Sources

Related Diseases for Bile Duct Disease

About this section

Diseases related to Bile Duct Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 common bile duct disease 12.2
2 cholangitis 11.2
3 caroli disease 10.9
4 marfan syndrome/loeys-dietz syndrome/familial thoracic aortic aneurysms and dissections 10.3 ABCB11 ABCB4 ATP8B1
5 autosomal dominant tubulointerstitial kidney disease, muc1-related 10.3 ABCB11 ATP8B1 NR1H4
6 gallbladder disease 1 10.3 ABCB11 ABCB4 ATP8B1
7 kohler's disease 10.2 ABCB4 ALB GPT
8 ebstein anomaly 10.2 GGT1 SLC25A13
9 amyotrophic lateral sclerosis 3 10.2 ABCB11 ABCB4 ATP8B1 NR1H4
10 cholestasis, benign recurrent intrahepatic, 2 10.2 ABCB11 ABCB4 ATP8B1 NR1H4
11 ringed hair 10.2 GGT1 GPT SLC10A1
12 fallopian tube leiomyosarcoma 10.2 ALB CCK GPT
13 pyelitis 10.2 ABCC2 ALB GPT
14 fibrosarcoma of bone 10.2 CYP7A1 NR1H4 NR1I2
15 aneurysm, intracranial berry, 9 10.2 CYP7A1 NR1H4 NR1I2
16 patent foramen ovale 10.2 ALB GPT NR1H4 SLC10A1
17 mitochondrial dna depletion syndrome 7 10.2 ABCC2 ABCC3 ABCC4
18 acute cholangitis 10.2 ABCB11 ABCB4 ALB NR1I2
19 congenital hypoplastic anemia 10.1 ALB GPT SLC25A13
20 paranasal sinus sarcoma 10.1 ALB GGT1 GPT SLC25A13
21 tolosa-hunt syndrome 10.1 GGT1 GGT2
22 microcephaly, progressive, seizures, and cerebral and cerebellar atrophy 10.1 ABCB4 GGT1 GPT NR1I2
23 chronic venous insufficiency 10.1 GGT1 GGT2
24 pseudoarthrosis 10.1 ABCB4 ALB GGT1 NR1H4
25 cholestasis, intrahepatic, of pregnancy, 1 10.1 ABCB11 ABCB4 ATP8B1 GGT1 NR1H4
26 bile duct cystadenocarcinoma 10.1 ALB GGT1 GGT2 GPT
27 borderline leprosy 10.1 ABCB4 ALB CCK CYP7A1 GPT NR1H4
28 hereditary spastic paraplegia 10.0 ALB GGT1 GPT SLC10A1
29 noninfectious dermatoses of eyelid 10.0 ALB GGT1 GPT
30 cholestasis, benign recurrent intrahepatic 10.0
31 perforation of bile duct 10.0
32 cholestasis 10.0
33 bacterial meningitis 10.0 ABCB11 ABCB4 ALB GGT1 GPT NR1I2
34 malignant visceral pleura tumor 10.0 GGT1 GGT2
35 lymphoid leukemia 9.9 ABCB11 ABCB4 ALB ATP8B1 GGT1 GPT
36 sclerosing cholangitis 9.9
37 childhood malignant hemangiopericytoma 9.9 ABCB11 ALB CCK GGT1 GGT2 NR1I2
38 campylobacteriosis 9.8 ABCC2 ABCC3 CYP7A1 GGT1 GPT SLC10A1
39 echinococcosis 9.7
40 intrahepatic cholangiocarcinoma 9.7
41 chronic rheumatic pericarditis 9.6 ABCB11 ABCB4 ABCC2 ALB ATP8B1 GGT1
42 eclampsia 9.4 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1
43 heart aneurysm 8.6 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ALB
44 gastrointestinal adenoma 8.5 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ALB

Graphical network of the top 20 diseases related to Bile Duct Disease:



Diseases related to Bile Duct Disease
Sources

Symptoms & Phenotypes for Bile Duct Disease

About this section

UMLS symptoms related to Bile Duct Disease:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Bile Duct Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.66 ABCC3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.66 GGT2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.66 ABCC3 GGT1 GGT2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.66 GGT2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.66 ABCC3 GGT1 GGT2 ABCB11
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.66 ABCC3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.66 GGT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.66 ABCC3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.66 ABCC3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.66 ABCC3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.66 ABCB11
12 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.66 GGT2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.66 ABCB11
14 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.66 GGT1 GGT2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.66 ABCB11
16 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.66 ABCB11

MGI Mouse Phenotypes related to Bile Duct Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.83 ABCC3 ABCC4 ALB ATP8B1 CCK CYP7A1
2 liver/biliary system MP:0005370 9.36 ABCB11 ABCB4 ABCC2 ABCC3 ALB ATP8B1
Sources

Drugs & Therapeutics for Bile Duct Disease

About this section

Drugs for Bile Duct Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 436)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128-13-2 31401
4
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
7
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
8
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
9
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2 2078-54-8 4943
10
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
11
Etomidate Approved Phase 4 33125-97-2 36339 667484
12
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
13
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
14
Secretin Approved, Investigational Phase 4,Early Phase 1 108153-74-8
15
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
16
Indomethacin Approved, Investigational Phase 4,Phase 2,Phase 3 53-86-1 3715
17
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
18
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919
19
Tauroursodeoxycholic acid Approved, Investigational Phase 4,Phase 3 14605-22-2 12443252
20
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
21
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
22
Vancomycin Approved Phase 4,Phase 3,Phase 1 1404-90-6 441141 14969
23
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1 443-48-1 4173
24
Meperidine Approved Phase 4 57-42-1 4058
25
Levobupivacaine Approved Phase 4 27262-47-1 92253
26
Cholecystokinin Approved Phase 4 9011-97-6
27
Ofloxacin Approved Phase 4 82419-36-1 4583
28
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
29
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
30 Pinaverium Approved Phase 4 59995-65-2
31
Abatacept Approved Phase 4 332348-12-6 10237
32
Coal tar Approved Phase 4 8007-45-2
33
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
34
Sorbitol Approved Phase 4 50-70-4 5780
35
Choline Approved, Nutraceutical Phase 4 62-49-7 305
36
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
37
Butyric Acid Experimental Phase 4 107-92-6 264
38 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 glucagon Phase 4
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
41 Flurbiprofen axetil Phase 4
42 Cholagogues and Choleretics Phase 4,Phase 3,Phase 2,Phase 1
43 Adjuvants, Anesthesia Phase 4,Phase 3
44 Narcotics Phase 4,Phase 3
45 GABA Agents Phase 4,Phase 3
46 GABA Modulators Phase 4
47 Nefopam Phase 4
48 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
50 Soybean oil, phospholipid emulsion Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 697)
id Name Status NCT ID Phase
1 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
2 Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction Unknown status NCT01514214 Phase 4
3 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
4 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
5 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4
6 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4
7 Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Unknown status NCT02013986 Phase 4
8 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4
9 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
10 Effects of Calot's Triangle Block for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy: a Prospective, Randomized, Double-blind, Controlled, Clinical Trial Unknown status NCT02300480 Phase 4
11 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
12 Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice Unknown status NCT00731419 Phase 4
13 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
14 The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent Completed NCT01862198 Phase 4
15 A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers Completed NCT01134848 Phase 4
16 Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia Completed NCT02298218 Phase 4
17 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
18 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4
19 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
20 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
21 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
22 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
23 Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis Completed NCT01510860 Phase 4
24 Spy II Clinical Registry Completed NCT00751998 Phase 4
25 Cholecyst- Versus Cystic Duct Cholangiography During Laparoscopic Cholecystectomy Completed NCT01103570 Phase 4
26 Balloon Catheter vs. Basket Catheter for Endoscopic Bile Duct Stone Extraction Completed NCT02909595 Phase 4
27 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
28 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents Completed NCT01315522 Phase 4
29 Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
30 A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects Completed NCT02496221 Phase 4
31 Pain Reduction After Cholecystectomy Completed NCT01199406 Phase 4
32 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4
33 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Recruiting NCT02605213 Phase 4
34 Endoscopic Treatment of Difficult Bile Duct Stones: Spyglass + EHL x Balloon Dilation of the Papilla Recruiting NCT02703077 Phase 4
35 Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction Recruiting NCT02833103 Phase 4
36 WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study Recruiting NCT01543256 Phase 4
37 The Discovery of the Double Sphincter in Gallbladder Recruiting NCT01998451 Phase 4
38 Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis Recruiting NCT02057679 Phase 4
39 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Active, not recruiting NCT02464020 Phase 4
40 Preventing Cholestasis Using SMOFLipid® Active, not recruiting NCT01585935 Phase 4
41 Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Active, not recruiting NCT02078882 Phase 4
42 Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC Active, not recruiting NCT02535117 Phase 4
43 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4
44 Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal Not yet recruiting NCT03082469 Phase 4
45 The Effect of Individualized Precision Therapy Programs in Patients With BTC Not yet recruiting NCT02943031 Phase 4
46 Laparoscopic Surgery VS RFA for Recurrent HCC Not yet recruiting NCT02785380 Phase 4
47 Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders Terminated NCT01373918 Phase 4
48 Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions Terminated NCT02633384 Phase 4
49 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4
50 Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients Terminated NCT00820612 Phase 4

Search NIH Clinical Center for Bile Duct Disease

Cochrane evidence based reviews: bile duct diseases

Sources

Genetic Tests for Bile Duct Disease

About this section
Sources

Anatomical Context for Bile Duct Disease

About this section

MalaCards organs/tissues related to Bile Duct Disease:

39
Liver, Kidney, Small Intestine
Sources

Publications for Bile Duct Disease

About this section

Articles related to Bile Duct Disease:

(show all 16)
id Title Authors Year
1
Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. ( 24555589 )
2014
2
CHOLANGIOSCOPY IN BILE DUCT DISEASE: a case series. ( 25296087 )
2014
3
Echinococcosis mimicking autoimmune or malignant bile duct disease. ( 24022203 )
2013
4
Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients. ( 23085575 )
2013
5
Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). ( 21762903 )
2011
6
Biliary cytokeratin expression but not CD56 (N-CAM) expression aids in the differential diagnosis of non-neoplastic bile duct diseases. ( 20538416 )
2010
7
Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E- NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases. ( 15072822 )
2004
8
Treatment of extrahepatic bile duct disease in infancy and early childhood. ( 11847446 )
2002
9
Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. ( 8201224 )
1994
10
Bile duct disease: prospective comparison of ERCP, CT, and fat suppression MRI. ( 1426853 )
1992
11
Rejection of murine congenic bile ducts: a model for immune-mediated bile duct disease. ( 1537528 )
1992
12
Primary sclerosing cholangitis, a vanishing bile duct disease. ( 3658059 )
1987
13
Radiomanometry in the diagnosis of common bile duct disease. ( 4445925 )
1974
14
Radiomanometry, flow rates, and cholangiography in the evaluation of common bile duct disease. A study of 220 cases. ( 5058873 )
1972
15
The incidence of common bile duct disease following surgical exploration. ( 14352652 )
1955
16
Gallbladder and bile duct disease. ( 14392255 )
1955
Sources

Variations for Bile Duct Disease

About this section
Sources

Expression for Bile Duct Disease

About this section
Search GEO for disease gene expression data for Bile Duct Disease.
Sources

Pathways for Bile Duct Disease

About this section

Pathways related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Metabolism 62
Show member pathways
 13.97 ABCB11 ABCB4 ABCC3 ALB CYP7A1 CYP8B1
2
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds 62
Show member pathways
 13.27 ABCB4 ABCC2 ABCC3 ABCC4 ALB ATP8B1
3
Synthesis of bile acids and bile salts 62
Show member pathways
 12.17 ABCB11 ABCC3 ALB CYP7A1 CYP8B1 NR1H4
4
Blood-Brain Barrier and Immune Cell Transmigration: Pathways Overview 61
Show member pathways
 12.08 ABCC2 ABCC3 ABCC4 SLCO1C1
5
NRF2 pathway 1
11.99 ABCC2 ABCC3 ABCC4 GGT1 GGT2
6
Hepatic ABC Transporters 60
Show member pathways
 11.9 ABCB11 ABCB4 ABCC2 SLC10A1 SLCO1A2
7
Statin Pathway - Generalized, Pharmacokinetics 58
Show member pathways
 11.71 ABCB11 ABCC2 ABCC4 SLCO1A2
8
Bile secretion 37
11.71 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 CYP7A1
9
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics 58
Show member pathways
 11.65 ABCC2 ABCC3 ABCC4
11
Antifolate resistance 37
11.18 ABCC2 ABCC3 ABCC4
12
Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling 1
11.05 ABCC2 ABCC3 ABCC4
13
Farnesoid X Receptor Pathway 1
11.01 ABCB11 ABCB4 CYP7A1 CYP8B1 NR1H4 SLC10A1
14
Methotrexate Pathway, Pharmacokinetics 58
Show member pathways
 10.97 ABCC2 ABCC3 ABCC4 SLCO1A2
15
Lamivudine Pathway, Pharmacokinetics/Pharmacodynamics 58
10.89 ABCC2 ABCC3 ABCC4
16
Drug Induction of Bile Acid Pathway 1
10.84 ABCB11 ABCC2 ABCC3 ABCC4 CYP7A1 NR1H4
17
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 58
10.77 ABCC3 NR1I2
18
Nuclear Receptors in Lipid Metabolism and Toxicity 1
10.77 ABCB11 ABCB4 ABCC2 ABCC3 CYP7A1 CYP8B1
19
Taxane Pathway, Pharmacokinetics 58
10.7 ABCC2 NR1I2
20
Vinka Alkaloid Pathway, Pharmacokinetics 58
10.56 ABCC2 ABCC3
Sources

GO Terms for Bile Duct Disease

About this section

Cellular components related to Bile Duct Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.56 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1
2 brush border membrane GO:0031526 9.33 ABCB4 ABCC2 ATP8B1
3 intercellular canaliculus GO:0046581 8.8 ABCB11 ABCB4 ABCC2
4 integral component of membrane GO:0016021 10.07 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1

Biological processes related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.91 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 SLC10A1
2 bile acid biosynthetic process GO:0006699 9.63 ABCB11 CYP7A1 CYP8B1
3 sodium-independent organic anion transport GO:0043252 9.61 ALB SLCO1A2 SLCO1C1
4 phospholipid translocation GO:0045332 9.58 ABCB4 ATP8B1
5 leukotriene biosynthetic process GO:0019370 9.58 GGT1 GGT2
6 organic anion transport GO:0015711 9.58 ABCC2 SLCO1A2 SLCO1C1
7 bile acid metabolic process GO:0008206 9.57 ATP8B1 NR1H4
8 glutathione catabolic process GO:0006751 9.56 GGT1 GGT2
9 zymogen activation GO:0031638 9.55 GGT1 GGT2
10 thyroid hormone transport GO:0070327 9.54 ABCC2 SLCO1C1
11 drug export GO:0046618 9.52 ABCB4 NR1I2
12 response to antineoplastic agent GO:0097327 9.51 ABCB4 ABCC2
13 xenobiotic transport GO:0042908 9.5 ABCB4 ABCC3 NR1I2
14 regulation of bile acid biosynthetic process GO:0070857 9.49 CYP7A1 NR1H4
15 canalicular bile acid transport GO:0015722 9.48 ABCB11 ABCC2
16 drug transmembrane transport GO:0006855 9.46 ABCB4 ABCC2 ABCC3 ATP8B1
17 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.26 ABCB11 ABCC2 ABCC3 ABCC4
18 bile acid and bile salt transport GO:0015721 9.23 ABCB11 ABCC3 ALB ATP8B1 NR1H4 SLC10A1
19 transport GO:0006810 10.03 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ALB

Molecular functions related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 ATPase activity GO:0016887 9.72 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4
2 transporter activity GO:0005215 9.65 ABCB11 ABCC2 ABCC3 SLC25A13 SLC51B
3 gamma-glutamyltransferase activity GO:0003840 9.49 GGT1 GGT2
4 glutathione hydrolase activity GO:0036374 9.48 GGT1 GGT2
5 thyroid hormone receptor activity GO:0004887 9.46 NR1H4 NR1I2
6 xenobiotic-transporting ATPase activity GO:0008559 9.43 ABCB4 ABCC3
7 bile acid transmembrane transporter activity GO:0015125 9.4 SLC10A1 SLCO1A2
8 bile acid-exporting ATPase activity GO:0015432 9.37 ABCB11 ABCC3
9 ATPase-coupled anion transmembrane transporter activity GO:0043225 9.33 ABCC2 ABCC3 ABCC4
10 organic anion transmembrane transporter activity GO:0008514 9.26 ABCC2 ABCC3 SLCO1A2 SLCO1C1
11 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.02 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4
Sources

Sources for Bile Duct Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....